查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1587116

慢性阻塞性肺病治疗市场：按药物类型、产品类型、测试、应用划分 - 2025-2030 年全球预测

Chronic Obstructive Pulmonary Disease Treatment Market by Drug Type (Antibiotic, Anticholinergic, Beta2-agonists), Product (Inhalers, Nebulizers), Test, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

慢性阻塞性肺病治疗市场2023年估值为775亿美元，预计到2024年将达到833.9亿美元，复合年增长率为7.69%，预计到2030年将达到1302.4亿美元。

慢性阻塞性肺病(COPD) 治疗包括多种旨在控制症状、改善生活品质和减缓疾病进展的治疗方法。对有效慢性阻塞性肺病治疗的需求源于这种使人衰弱的疾病的日益流行，这主要是由于空气污染加剧、吸烟率上升和人口老化造成的。这些治疗用于减少呼吸困难、预防慢性恶化并增强体力活动。最终用途范围包括医院、诊所和家庭护理机构，使用支气管扩张剂、皮质类固醇、氧气疗法和肺部復健等选项。慢性阻塞性肺病治疗市场的关键成长要素包括吸入器技术的进步、针对发炎途径的新型生技药品的推出以及患者意识的提高。数位健康整合存在市场机会，例如远端监控和远端医疗平台，可以提供个人化的治疗计划和依从性支援。然而，重大挑战仍然存在，包括高昂的药物开发成本、严格的法律规范以及长期药物治疗的副作用。此外，慢阻肺早期存在许多误诊和治疗不充分的情况，也阻碍了市场的拓展。创新途径应着重于用于早期诊断的生物标记、减少全身副作用的下一代药物传递系统，以及修復肺组织的细胞疗法等再生医学方法。该市场本质上是动态的，其特点是学名药的稳定进入以及老牌製药公司和新兴生物技术公司之间的竞争。为了实现最佳业务成长，公司应优先考虑研究合作并投资以患者为中心的解决方案，以满足个人化和微创治疗中未满足的需求。采用适应不断变化的患者偏好和治疗方法进展的敏捷方法可以增强您的市场地位并推动永续成长。

主要市场统计
基准年[2023] 775亿美元
预测年份 [2024] 833.9亿美元
预测年份 [2030] 1302.4亿美元
复合年增长率（%） 7.69%

市场动态：快速发展的慢性阻塞性肺病治疗市场的关键市场洞察

供需的动态交互作用正在改变慢性阻塞性肺病治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 老年人口增加和不健康的生活方式
    • 气喘和慢性阻塞性肺病（COPD）患者数量不断增加
    • 消费者对数位气喘护理设备的认识不断增强
  • 市场限制因素
    • 政府对吸入器核准有严格的规定
  • 市场机会
    • 气喘治疗设备和新产品发布的快速技术进步
    • 居家照护治疗设备需求旺盛
  • 市场挑战
    • 吸入器的价格压力不断增加且专利到期

波特五力：开拓慢性阻塞性肺病治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解慢性阻塞性肺病治疗市场的外部影响

外部宏观环境因素在塑造慢性阻塞性肺病治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解慢性阻塞性肺病治疗市场的竞争格局

对慢性阻塞性肺病治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵慢性阻塞性肺病治疗市场供应商的绩效评估

FPNV 定位矩阵是评估慢性阻塞性肺病治疗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划慢性阻塞性肺病治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对慢性阻塞性肺病治疗市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 老年人口增加和不健康的生活方式
      • 气喘和慢性阻塞性肺病(COPD) 的地理定位数
      • 意识提升对数位气喘护理设备的认识
    • 抑制因素
      • 政府对吸入器核准的严格规定
    • 机会
      • 气喘治疗设备和新产品发布的快速技术进步
      • 居家照护治疗设备需求量大
    • 任务
      • 吸入器的价格压力不断增加且专利到期
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章慢性阻塞性肺病治疗市场（依药物类型）

  • 抗生素
  • 抗胆碱能药
  • β2促效剂
  • 甲基黄嘌呤类
  • 口服类固醇
  • 磷酸二酯酶4抑制剂

第七章慢性阻塞性肺病治疗市场：副产品

  • 吸入器
  • 喷雾器

第八章慢性阻塞性肺病治疗市场测试

  • 动脉血气测试
  • 胸部X光检查
  • 电脑断层扫描
  • 基因检测
  • 肺功能检查

第九章慢性阻塞性肺病治疗市场：依应用分类

  • 慢性支气管炎
  • 气肿
  • 难治性气喘

第十章北美及南美洲慢性阻塞性肺病治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区慢性阻塞性肺病治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲慢性阻塞性肺病治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Adamis Pharmaceuticals Corporation
  • Almirall, SA
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Chiesi Farmaceutici SpA
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Orion Oyj
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-43676CF42C41

The Chronic Obstructive Pulmonary Disease Treatment Market was valued at USD 77.50 billion in 2023, expected to reach USD 83.39 billion in 2024, and is projected to grow at a CAGR of 7.69%, to USD 130.24 billion by 2030.

Chronic Obstructive Pulmonary Disease (COPD) treatment encompasses an array of therapeutic approaches aimed at managing symptoms, improving quality of life, and slowing disease progression. The necessity for effective COPD treatments arises from the rising prevalence of this debilitating disease, largely driven by increased air pollution, smoking rates, and an aging population. These treatments find application in reducing breathlessness, preventing chronic exacerbations, and enhancing physical activity. The end-use scope includes hospitals, clinics, and home care settings, where options such as bronchodilators, corticosteroids, oxygen therapy, and pulmonary rehabilitation are utilized. Key growth influencers in the COPD treatment market include advancements in inhaler technologies, the introduction of novel biologics targeting inflammatory pathways, and increasing patient awareness. Market opportunities lie within the digital health integration-like remote monitoring and telemedicine platforms-offering personalized treatment plans and adherence support. However, substantial challenges remain, such as high drug development costs, stringent regulatory frameworks, and the adverse side effects of long-term pharmacotherapy. Additionally, the frequent misdiagnosis and under-treatment in early-stage COPD hinder market expansion. Innovation avenues should focus on biological markers for early diagnosis, next-generation drug delivery systems reducing systemic side effects, and regenerative medicine approaches like cellular therapies aimed at lung tissue restoration. The market is inherently dynamic, characterized by a steady entry of generic products and the competition between established pharmaceutical players and emerging biotechnology firms. For optimal business growth, companies should prioritize research collaborations and invest in patient-centric solutions addressing unmet needs in personalized and minimally invasive therapies. Embracing an agile approach that aligns with evolving patient preferences and therapeutic advancements will enhance market position and drive sustained growth.

KEY MARKET STATISTICS
Base Year [2023] USD 77.50 billion
Estimated Year [2024] USD 83.39 billion
Forecast Year [2030] USD 130.24 billion
CAGR (%) 7.69%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Chronic Obstructive Pulmonary Disease Treatment Market

The Chronic Obstructive Pulmonary Disease Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase in geriatric population and rise in unhealthy lifestyle
    • Geoing number of asthma and chronic obstructive pulmonary disease (COPD)
    • Increasing consumer awareness toward digital asthma care devices
  • Market Restraints
    • Stringent regulations for inhaler approvals by the government
  • Market Opportunities
    • Rapid technological advancements and new product launches in the asthma devices
    • High demand for home care therapeutic devices
  • Market Challenges
    • Increased pricing pressures and patent expiries on inhalers

Porter's Five Forces: A Strategic Tool for Navigating the Chronic Obstructive Pulmonary Disease Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Chronic Obstructive Pulmonary Disease Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Chronic Obstructive Pulmonary Disease Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Chronic Obstructive Pulmonary Disease Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Chronic Obstructive Pulmonary Disease Treatment Market

A detailed market share analysis in the Chronic Obstructive Pulmonary Disease Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Chronic Obstructive Pulmonary Disease Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Chronic Obstructive Pulmonary Disease Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Chronic Obstructive Pulmonary Disease Treatment Market

A strategic analysis of the Chronic Obstructive Pulmonary Disease Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Chronic Obstructive Pulmonary Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adamis Pharmaceuticals Corporation, Almirall, S.A., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Inc., Chiesi Farmaceutici S.p.A., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Orion Oyj, Sunovion Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Chronic Obstructive Pulmonary Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Antibiotic, Anticholinergic, Beta2-agonists, Methylxanthines, Oral Corticosteroid, and Phosphodiesterase-4 Inhibitors.
  • Based on Product, market is studied across Inhalers and Nebulizers.
  • Based on Test, market is studied across Arterial Blood Gas Test, Chest X-ray Test, CT scan, Genetic Test, and Lung Functional Test.
  • Based on Application, market is studied across Chronic Bronchitis, Emphysema, and Refractory Asthma.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in geriatric population and rise in unhealthy lifestyle
      • 5.1.1.2. Geoing number of asthma and chronic obstructive pulmonary disease (COPD)
      • 5.1.1.3. Increasing consumer awareness toward digital asthma care devices
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulations for inhaler approvals by the government
    • 5.1.3. Opportunities
      • 5.1.3.1. Rapid technological advancements and new product launches in the asthma devices
      • 5.1.3.2. High demand for home care therapeutic devices
    • 5.1.4. Challenges
      • 5.1.4.1. Increased pricing pressures and patent expiries on inhalers
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Chronic Obstructive Pulmonary Disease Treatment Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Antibiotic
  • 6.3. Anticholinergic
  • 6.4. Beta2-agonists
  • 6.5. Methylxanthines
  • 6.6. Oral Corticosteroid
  • 6.7. Phosphodiesterase-4 Inhibitors

7. Chronic Obstructive Pulmonary Disease Treatment Market, by Product

  • 7.1. Introduction
  • 7.2. Inhalers
  • 7.3. Nebulizers

8. Chronic Obstructive Pulmonary Disease Treatment Market, by Test

  • 8.1. Introduction
  • 8.2. Arterial Blood Gas Test
  • 8.3. Chest X-ray Test
  • 8.4. CT scan
  • 8.5. Genetic Test
  • 8.6. Lung Functional Test

9. Chronic Obstructive Pulmonary Disease Treatment Market, by Application

  • 9.1. Introduction
  • 9.2. Chronic Bronchitis
  • 9.3. Emphysema
  • 9.4. Refractory Asthma

10. Americas Chronic Obstructive Pulmonary Disease Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Adamis Pharmaceuticals Corporation
  • 3. Almirall, S.A.
  • 4. Astellas Pharma Inc.
  • 5. AstraZeneca PLC
  • 6. Bayer AG
  • 7. Boehringer Ingelheim Pharmaceuticals, Inc.
  • 8. Chiesi Farmaceutici S.p.A.
  • 9. F. Hoffmann-La Roche Ltd.
  • 10. GlaxoSmithKline Plc
  • 11. Johnson & Johnson Services, Inc.
  • 12. Merck & Co., Inc.
  • 13. Novartis AG
  • 14. Orion Oyj
  • 15. Sunovion Pharmaceuticals Inc.
  • 16. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ANTICHOLINERGIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA2-AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY METHYLXANTHINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ORAL CORTICOSTEROID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ARTERIAL BLOOD GAS TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CHEST X-RAY TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CT SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GENETIC TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY LUNG FUNCTIONAL TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CHRONIC BRONCHITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY EMPHYSEMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REFRACTORY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 196. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023